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netic resonance imaging (DCE-MRI) correlate more strongly with
reduction in pain severity than changes in static synovial volume. The
aim of this analysis was to determine the impact of a PFJ brace on
synovitis as assessed by change in synovial enhancement using DCE-
MRI.
Methods: One hundred and twenty six people aged between 40 and 70
years with PFJ OA were recruited into a randomised clinical trial of a
patellar brace. Participants were randomised to an intervention
(wearing brace) and a control group (no brace) for six weeks. Subjects
were assessed at baseline and at 6 weeks for pain using the KOOS
questionnaire and also a visual analogue score (VAS) scored from 0-
100mm for a nominated physical activity (VASNA). They also had DCE-
MRI of the symptomatic knee performed at baseline and at 6 weeks.
Dynamic synovial parameters were calculated based on the enhance-
ment of synovium with contrast including; maximum rate of
enhancement (max-grad), late relative enhancement (late-rel), max-
imum enhancement (max) and volume transfer coefﬁcient (ktrans). We
used a paired t-test to look at within group change in both pain and
DCE-MRI parameters before and after intervention and an unpaired t-
test to look at the between group difference in the change in these
parameters.
Results: Subjects’ mean age was 55.5 years (SD ¼ 7.5) and 72 (57.1%)
were female. Pain improved signiﬁcantly within the intervention group
though not the control group. There was a signiﬁcant between group
difference in the change in both KOOS and VASNA, see Table. Within
controls there was a reduction in all of the dynamic parameters
between baseline and follow up. This was signiﬁcant for volume
transfer coefﬁcient (within group difference in ktrans ¼ -0.003) and
also maximum rate of enhancement (within group difference in max-
grad ¼ -0.198). Within the intervention group there was a small
increase (worsening) in all of the dynamic MRI parameters between
baseline and 6 weeks follow up though none of these differences was
statistically signiﬁcant. There was a signiﬁcant difference in the change
in maximum rate of enhancement (max) between the intervention and
control groups.
Conclusions: Patellofemoral joint brace therapy for patients with
symptomatic patellofemoral knee OA does not reduce synovitis as
suggested by change in synovial enhancement using DCE-MRI. Pain
reduction following brace therapy can not therefore be explained by
change in synovitis.Table 1
Changes in Dynamic MRI Factors Following Brace Intervention
Variables No brace group (N¼63) Brace group (N¼63)
Within group mean diff (95% CI) p Within group mean diff (95% CI) p Between-group mean diff (95% CI) p
ktrans 0.003 (0.006 to 0.000) 0.05 0.001 (0.003 to 0.005) 0.63 0.002 (0.009 to 0.001) 0.11
max_grad 0.198 (0.345 to 0.050) 0.01 0.171 (0.013 to 0.356) 0.07 0.116 (0.599 to 0.139) <0.01
late_rel 0.102 (0.280 to 0.076) 0.25 0.010 (0.175 to 0.195) 0.91 0.128 (0.367 to 0.142) 0.38
max 0.161 (0.357 to 0.036) 0.11 0.045 (0.166 to 0.256) 0.67 0.143 (0.491 to 0.079) 0.15
Pain on nominated activity VAS 0.13 (0.64 to 0.38) 0.61 1.82 (2.39 to 1.24) <0.01 0.38 (0.93 to 2.44) <0.01
KOOS Pain Subscale Score 1.71 (1.66 to 5.08) 0.31 8.78 (4.36 to 13.20) <0.01 2.75 (12.51 to 1.61) 0.0141
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Purpose:While osteoarthritis (OA) is the most frequent type of arthritis
in the population, relatively little attention has been paid to patients’
perceptions of the impact of their disease and the barriers they face in
receiving care. This study examined current treatments and barriers to
treatment, as well as perceptions around decision making and the
preferences of patients for physician input into their OA treatment.
Methods: A poll of people with arthritis was commissioned to gather
data on patient perceptions with the purpose of improving the infor-
mation presented on The Arthritis Society of Canada website.
Respondents were asked for their disease diagnosis; impact of arthritis
(e.g., pain, fatigue, disability with activities and social roles); barriers
and challenges in getting care; and preferences for physicianinvolvement in care decisions. Most questions were on a 1 to 5 scale
ranging from 1 ¼ no impact/importance to 5 ¼ extreme impact/
importance. Scores are reported as means or percentages unless oth-
erwise stated.
Results: Of the 1715 respondents, 922 (53.8%) reported osteoarthritis
(OA) and 588 (34.3%) reported OA as their sole type of arthritis.We focus
on those with OA as a sole diagnosis. Eighty two percent were female;
57% were aged 5 years. The mean pain intensity was 5.9 on a 1-10 scale
with 70% reporting pain at least once aweek. Themean number of joints
affectedwas 3.8 (out of 13). However, 44% of participants reported taking
no medications for their OA. The impact of OA on daily activities was
moderatewithmean scores in the range of 2.2-3.0 out of 5 for family and
social-related activities. The greatest impact of OAwas for exercise (3.3)
and intimate relations (4.4). Respondents reported controlling pain,
mobility and stiffness, loss of strength, fatigue, low energy and difﬁculty
sleeping as being of high importance (range ofmean scores 4.1-4.4) with
no differences by age. Overall 75% of respondents reported at least one
challenge in getting treatment with the top 3 challenges being a lack of
affordable treatment (30.1%), long wait times for appointments (28.3%),
and a perceived absence of beneﬁcial treatment (e.g., ”don’t think any-
thing can be done”) (26.3%). Costs for treatments like physiotherapy and
over-the-counter medication were noted in particular. Respondents
rated highly the importance of physicians considering their input when
making decisions related to prescription medication (mean ¼ 4.4) and
treatments such as surgery or physiotherapy (mean ¼ 4.4). However
they expressed lower perceived importance for seeking physician input
before deciding on treatments such as diet and exercise (mean¼3.7) and
over-the counter-medications (mean ¼ 3.8).
Conclusions: Despite pain, a moderate impact on valued roles and
activities, and a high importance of controlling a range of symptoms,
two-ﬁfths of people with OAwere not taking any medications, which is
in line with ﬁndings from other studies. Of concern was that most
respondents reported challenges and hardships with getting treatment,
including costs not covered by the health care system and a perception
that little was available to them in the way of efﬁcacious care for OA.
Moreover, clinician input was not always seen as important in man-
agement of all aspects of OA. There is a clear need for better information
for patients on what can be done to control their illness and for inter-
ventions to minimize barriers in accessing appropriate treatments.
Additional research on decision-making preferences related to OA
treatment would be beneﬁcial in addressing a patient-centred approach
to OA management.42
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Purpose: Folate-based radiotracers have been used in patients with
cancer and inﬂammatory diseases to visualize folate receptor express-
ing cells using PET or SPECT techniques. Activated macrophages express
folate receptor beta (FR-b) and this allows speciﬁc imaging of these cells
in-vivo. From previous work using SPECT imaging to visualize folate
receptor expressingmacrophages in both animal models and in patients
with OA we know that macrophages are present in OA affected joints.
However, it remains unclear what role these macrophages play in the
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A49different stages of OA and whether they can be inﬂuenced by treatment
with corticosteroids. Aim of the study. To understand which macro-
phage subtypes express the folate receptor and can be visualized using
SPECT imaging and whether these macrophages are affected by treat-
ment with corticosteroids (Triamcinolone).
Methods: In vivo. In twenty 16-week-old male Wistar rats severe
osteoarthritis was induced using a low dose intra-articular papain
injections in their left knee joints combined with exposure to a
moderate exercise protocol. Animals were divided over two groups:
ten rats served as untreated OA controls and ten rats were treated
during the experiment with weekly intra-articular injections of tri-
amcinolone acetonide (100ug in 70ul saline). After six weeks an in vivo
folate SPECT/CT scan and ex vivo EPIC-mCT and histology was obtained.
In vitro. We generated macrophages from human peripheral blood
monocytes in vitro by culturing them for 7 days in the presence of GM-
CSF (M1 proinﬂammatory phenotype) or M-CSF (M2 anti-inﬂamma-
tory phenotype). Subsequently, we treated the macrophages with LPS,
cytokines (IL-4, IL-10, IFN-y) or triamcinolone acetonide (1ug/ml). FR-b
(FOLR2) and macrophage marker expression was measured using
FACS.
Results: . Increased macrophage activation was seen on SPECT-scans
in OA induced knees versus control knees. Interestingly, treatment
with corticosteroids resulted in reduced OA severity but an increase
in activated macrophages seen on folate-SPECT imaging (ﬁgure1). On
human in vitro generated macrophages Folate receptor expression
was high in M2 macrophages and very low in M1 macrophages. There
were only small differences between M2 macrophages stimulated
with IL-4 or IL-10 alone. But when M2 macrophages were stimulated
with IL-4 and IL-10 simultaneously, the number of positive cells and
the ﬂuorescent intensity increased approximately 1.5 - 2 fold com-
pared to unstimulated M2 macrophages (ﬁgure2). Triamcinolone
acetonide signiﬁcantly reduced TNF-a production by M1 macro-
phages but did not affect M1 or M2 surface markers or folate receptor
expression.
Conclusions: Our data indicate that the increase in macrophage acti-
vation as seen on SPECT is most likely due to an increase in M2 anti-
inﬂammatory macrophages. However, from these results we cannot
infer which M2 subtype is present in our animal model. It is known that
corticosteroids can inﬂuence macrophage subtypes but we were not
able to show these effects in vitro, although in-vitro stimulation with
IL4þIl10 induced a folate receptor positive subtype within the M2
population. Our study suggests that not all macrophage subtypes are
detrimental. Maintaining the balance between the various macrophage
subtypes may thus be the key to maintain healthy joint homeostasis
and prevent osteophytosis.Figure 1. Macrophage activation determined after injection of 111In-DTPA-
folate using SPECT/CT in Papaine induced osteoarthritis (OA) combined
with moderate excercise. Representative sagittal SPECT/CT images of knee
joints from representative animals per experimental group. CT images
shown in black and white were used for anatomical reference, the SPECT
images are shown in color. Patellar bone is shown with osteophyte for-
mation highlighted in red.Figure 2. Fluorescent intensity of FOLR2 staining on human macrophages
differentiated in vitro. Average results from two representative experi-
ment are shown.
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S100 PROTEINS INDUCE CANONICAL WNT SIGNALING, WHICH
CAUSES INCREASED EXPRESSION OF MMPS IN THE SYNOVIUM
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Purpose: Many osteoarthritis (OA) patients show synovial activation,
which is thought to be involved in joint destruction. Previously, we
found that the alarmins S100A8 and A9, and various members of the
Wnt signaling pathway, including Wnt16, were highly increased in the
synovium of knee joints during experimental OA. WISP1, a downstream
protein of b-catenin-dependent canonical Wnt signaling, was increased
in both synovium and cartilage. S100A9 KO mice showed strongly
reduced pathology in experimental OA. Wnt signaling has been linked
to OA through activation of b-catenin, but the role of the synovium in
OA pathology under the inﬂuence of Wnt signaling is unclear. In this
study we investigated whether S100 proteins induce Wnt signaling and
determined the potency of Wnts to increase expression of cartilage-
degrading enzymes in the synovium.
Methods: Pathway analysis of microarray data from synovium of a
collagenase-induced OA was done using DAVID. Activation of Wnt sig-
naling was determined with b-catenin immunostaining of whole knee
joint sections. Gene expression was analyzed by qPCR. Human OA
synovial specimens were collected from joint replacement surgery and
stimulated with S100 or members of the Wnt signaling pathway or
blocked with the Wnt inhibitors FrzB and DKK-1.
Results: Pathway analysis showed enrichment of Wnt signaling in the
synovium during experimental OA. Because upregulation of both S100
andWnt proteins during experimental OA showed comparable kinetics,
we determined if S100 proteins could induce Wnt signaling. We found
that injections of S100A8 into mouse knee joints led to increased
expression of Wnt16 and WISP1 in the synovium and b-catenin accu-
mulation in the synovium and in the cartilage. Underlining an inter-
relationship between Wnt signaling and S100A8/9, we found less b-
catenin accumulation in both the synovium and cartilage during
experimental OA in S100A9 KOmice, suggesting a decrease in canonical
Wnt signaling. To determine the effects of canonical Wnt signaling in
the synovium, we overexpressed Wnt8a and Wnt16 in vivo in the
synoviumwith adenoviral vectors. This resulted in increased expression
of various MMPs in the synovium. To translate these ﬁndings to a
human situation, we stimulated human OA synovial tissues with
Wnt3a, as a model for a canonical Wnt, and WISP1. This led to sig-
niﬁcantly increased expression of MMP1, MMP9 and MMP13, whereas
the expression of the MMP inhibitors TIMP1 and 3 was not altered.
Next, we hypothesized that if Wnt signaling was increased in OA
synovium and that stimulation of synovium with members of the Wnt
